TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28784701
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (325 mg of inulin alone)
Study: 20386003
Drug: Enhanced depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced depression treatment
Study: 10943869
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day intravenous administration of anti‐IL‐10 monoclonal antibody (B‐N10) for 21 consecutive days
Study: 9077368
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (7 sessions during weeks 10 and 11)
Study: 3944815
Drug: Atropine 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 1.8 mg
Study: 3944815
Drug: Glycopyrrolate 0.6
Normalized name: glycopyrrolate 0.6 MG in 3 mL Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.6 mg
Study: 3944815
Drug: Glycopyrrolate 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.9 mg
Study: 29798500
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized dermatophagoides farinae drops for 12 months
Study: 27348641
Drug: Arnica ointment
Normalized name: Arnica Ointment
DrugBank: Arnica montana flower (DB14343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arnica ointment 10%
Study: 18674411
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules (3-12 mg/day) in older patients (>=75 years old)
Study: 18674411
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules (3-12 mg/day) in younger patients (less than 75 years old)
Study: 18674411
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules (3-12 mg/day) in patients with medial temporal atrophy
Study: 1510255
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg of metoclopramide
Study: 31347692
Drug: Fe‐Gly (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe‐Gly (60 mg Fe/kg)
Study: 31347692
Drug: Fe‐Gly (60,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe‐Gly (60, 80 mg Fe/kg)
Study: 31347692
Drug: Fe‐Gly (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe‐Gly (40 mg Fe/kg)
Study: 30693979
Drug: FeSO4 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeSO4 (60 mg Fe/kg)
Study: 27456147
Drug: Tunneled subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tunneled subcutaneous perineural catheter
Study: 7791603
Drug: Cover stories
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cover stories involving different pairs of element sets (e.g., objects and people)
Study: 7791603
Drug: Cover stories
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cover stories involving similar sets of people (e.g., doctors and doctors)
Study: 1787651
Drug: 4% branched-chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% branched-chain amino acid (BCAA) solution
Study: 31564503
Drug: MID‐O2 (midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: MID‐O2 (midazolam 1 mg kg‐1 IM)
Study: 19947365
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of the virus vaccine and chemotherapy (group A)
Study: 19947365
Drug: Therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with the vaccine alone (group B)
Study: 19947365
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen identical with that used in group A (group C)
Study: 17456483
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 20 mg tid for 4 weeks
Study: 12953348
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg coadministered with digoxin on Day 7
Study: 12953348
Drug: Aprepitant 80
Normalized name: aprepitant 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 80 mg coadministered with digoxin on Days 8 to 11
Study: 8682031
Drug: Flecainide 100
Normalized name: flecainide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 100 mg for paroxysmal supraventricular tachycardia
Study: 8682031
Drug: Flecainide 200
Normalized name: flecainide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 200 mg for paroxysmal atrial fibrillation
Study: 8682031
Drug: Propafenone 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 450 mg for paroxysmal supraventricular tachycardia
Study: 8682031
Drug: Propafenone 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 450 mg for paroxysmal atrial fibrillation
Study: 30680980
Drug: Alkalinized 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalinized 2% lidocaine (group L)
Study: 15383189
Drug: Budesonide/formoterol single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol single inhaler therapy (160/4.5 microg, 2 inhalations once daily)
Study: 15383189
Drug: Budesonide/formoterol single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol single inhaler therapy
Study: 15383189
Drug: Budesonide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (160 microg, 2 inhalations twice daily) plus terbutaline 0.4 mg as needed
Study: 11480224
Drug: Diazepam 15
Normalized name: diazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 15 mg intravenously (gr. 1)
Study: 11480224
Drug: Diazepam 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 30 mg orally (gr. 2)
Study: 31656294
Drug: Single-injection intraarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection intraarticular anesthesia
Study: 25517501
Drug: Bundle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bundle therapy (Tracheostomy followed by ventilator-Assisted breathing with reverse trendelenburg position, early goal-directed hemodynamic support, enteral nutrition by nasointestinal tube, effective antibiotic usage and large doses of expectorants)
Study: 25517501
Drug: Bundle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bundle therapy
Study: 17897912
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PE treatment)
Study: 9797798
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous doses of epoetin alfa (300, 450, 600, 900, 1200, 1350, 1800, and 2400 IU/kg)
Study: 9797798
Drug: Multiple subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple subcutaneous doses of epoetin alfa (150 IU/kg 3 times a week for 4 weeks)
Study: 9797798
Drug: Multiple subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple subcutaneous doses of epoetin alfa (600 IU/kg once per week for 4 weeks)
Study: 9797798
Drug: Single-dose regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose regimens of epoetin alfa
Study: 636501
Drug: No antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimicrobial chemotherapy
Study: 23248028
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mycophenolate mofetil (MMF) and pulse dexamethasone (DEX)
Study: 19076110
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg/ml, 1 ml/kg with DEX 1 microg/kg
Study: 19076110
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg/ml, 1 ml/kg
Study: 15051744
Drug: Azimilide dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide dihydrochloride 125 mg every 12 hours for 3 days, then every 24 hours for 5 days
Study: 15051744
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg coadministered on Day 8
Study: 11605290
Drug: Extracorporal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporal shock wave therapy (ESWT)
Study: 8046475
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of dipyridamole (0.14 mg/kg/min for 4 min, total 0.56 mg/kg)
Study: 8046475
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of dipyridamole (0.14 mg/kg/min for 6 min, total 0.84 mg/kg)
Study: 8046475
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of dipyridamole
Study: 31115462
Drug: Dietary fulvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fulvic acid supplementation (0.6 g kg‐1)
Study: 31115462
Drug: Dietary fulvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fulvic acid supplementation (1 g kg‐1)
Study: 31115462
Drug: Dietary fulvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fulvic acid supplementation (0.2 g kg‐1)
Study: 23412113
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine lozenge (4 mg deliverable)
Study: 21466258
Drug: Probiotic ice-cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic ice-cream containing Bifidobacterium lactis Bb12 and Lactobacillus acidophilus La5
Study: 21466258
Drug: Control ice-cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control ice-cream (placebo)
Study: 19884613
Drug: Bupropion plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion plus nicotine lozenge
Study: 2671414
Drug: Papaverine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (40 mg)
Study: 2671414
Drug: Papaverine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (20 mg) and Phentolamine (0.5 mg)
Study: 797539
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg clotrimazole troche, ten times a day
Study: 797539
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg clotrimazole troche, ten times a day
Study: 28525632
Drug: Pregabalin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (300 or 450 mg/day, twice daily)
Study: 27286894
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (DEX implant) only
Study: 27286894
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (DEX implant) with other RVO treatment
Study: 27286894
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (DEX implant) with ≥2 DEX implants
Study: 24674676
Drug: Both sevelamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sevelamer tablet forms
Study: 15649160
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 11.2 microg.kg(‐1)
Study: 15649160
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 15 microg.kg(‐1)
Study: 15649160
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 20 microg.kg(‐1)
Study: 7720945
Drug: Melatonin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (1 mg at 8:00 and 0.75 mg at 10:00 and 12:00 A.M.)
Study: 1974484
Drug: Arginine (ARG)
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine (ARG) 0.5 g/kg infused i.v. over 30 min with GHRH 1 microgram/kg i.v.
Study: 1974484
Drug: Arginine (ARG)
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine (ARG) 0.5 g/kg infused i.v. with Pyridostigmine (PD) 60 mg orally
Study: 1974484
Drug: Combined PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined PD and GHRH administration
Study: 7237220
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose droperidol (0.005 mg x kg‐1)
Study: 28447625
Drug: Dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements (combination pill)
Study: 21777972
Drug: HSCT (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSCT (200 mg/kg intravenous cyclophosphamide, 6.5 mg/kg intravenous rabbit antithymocyte globulin)
Study: 21777972
Drug: Cyclophosphamide (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (1.0 g/m² intravenous once per month for 6 months)
Study: 12536495
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (LMWH) administered by hypodermic injection for four weeks
Study: 22922591
Drug: CHF5074 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF5074 200 mg/d for 14 d
Study: 22922591
Drug: CHF5074 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF5074 400 mg/d for 14 d
Study: 22922591
Drug: CHF5074 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF5074 600 mg/d for 14 d
Study: 22922591
Drug: CHF5074 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF5074 (all doses)
Study: 8731665
Drug: Topical all‐trans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical all‐trans retinoic acid (0.1%)
Study: 8731665
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium lauryl sulphate (2%)
Study: 8731665
Drug: Vehicle creams
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle creams
Study: 1656739
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg on day 1 followed by 250 mg/day for days 2-5)
Study: 1656739
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg three times daily for 10 days)
Study: 30704508
Drug: Early care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early care bundle intervention including early and comprehensive management of symptoms, prompt detection and treatment of precipitating factors, intravenous nitrate boluses, low-dose diuretics, non-invasive ventilation, and preventive low-molecular-weight heparin.
Study: 28103942
Drug: Fluralaner topical
Normalized name: fluralaner Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluralaner topical solution
Study: 26009229
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (control)
Study: 23403682
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (14-day lansoprazole, amoxicillin, and clarithromycin)
Study: 23403682
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (5-day lansoprazole and amoxicillin followed by 5-day lansoprazole, clarithromycin, and metronidazole)
Study: 23403682
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (5-day lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Study: 23403682
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with 14-day bismuth-based quadruple therapy
Study: 23403682
Drug: Nonadherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadherence to initial therapy
Study: 23403682
Drug: Single-treatment course
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-treatment course analysis
Study: 22111592
Drug: Daily mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mixed nutritional supplement (SUP, ∼5.1 MJ·d⁻¹)
Study: 17946394
Drug: Simulation model
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulation model of glucose-insulin system
Study: 17946394
Drug: Open-loop insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-loop insulin infusion strategy
Study: 17946394
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin infusion strategy
Study: 11511139
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone
Study: 264798
Drug: Cyclophosphamide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide therapy
Study: 11511139
Drug: Methylprednisolone therapy
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone therapy
Study: 3427807
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% solution applied once daily for 1 day
Study: 3427807
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% solution applied once daily for 2 days (day one and day three)
Study: 3427807
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% solution applied once daily for 3 days (day one, day three and day six)
Study: 30040057
Drug: Drug-eluting balloon
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting balloon (DEB) percutaneous transluminal angioplasty (PTA)
Study: 23558673
Drug: IMRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT with XELOX chemotherapy
Study: 23558673
Drug: 3D-CRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D-CRT with 5-FU/FA chemotherapy
Study: 20504298
Drug: Ibuprofen 3
Normalized name: ibuprofen 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 3 x 400 mg oral for three days
Study: 20504298
Drug: Ciprofloxacin 2
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 2 x 250 mg (+1 placebo) oral for three days
Study: 18536783
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (110 microg once daily)
Study: 1295724
Drug: Levodropropizine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodropropizine (60 mg and 90 mg)
Study: 1295724
Drug: Dropropizine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dropropizine (60 mg and 90 mg)
Study: 21050973
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg) plus clopidogrel (75 mg) daily (AC group)
Study: 21050973
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg) alone daily (A group)
Study: 15271770
Drug: leflunomide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: leflunomide (20 mg once daily) plus sulfasalazine (2 g once daily)
Study: 15271770
Drug: placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus sulfasalazine (2 g once daily)
Study: 2086492
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of daily CDM administration
Study: 30088545
Drug: Intradetrusor onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intradetrusor onabotulinumtoxinA injections (300U)
Study: 30088545
Drug: Oral oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxybutynin (5mg, three times/day)
Study: 25128203
Drug: Matched control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched control group maintaining daily activity levels.
Study: 16096704
Drug: Gemcitabine 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1250 mg/m2 + vinorelbine 30 mg/m2 (GV group)
Study: 16096704
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m2 + gemcitabine 1000 mg/m2 + vinorelbine 25 mg/m2 (CGV group)
Study: 8054254
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g 4 times per day)
Study: 1612951
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy multiple daily fractionation (MDF), using 3 daily fractions of 1.25 Gy each, up to a total dose of 37.5 Gy in 12 days.
Study: 1612951
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy conventional fractionation (CF), for a total dose of 50 Gy/5 weeks.
Study: 1612951
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (cystectomy alone).
Study: 31570100
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active medication treatment
Study: 31570100
Drug: General factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: General factors affecting treatment retention
Study: 26526623
Drug: Toremifene 60
Normalized name: toremifene 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 60 mg plus ADT (TOPADT)
Study: 23016517
Drug: Androgen-deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-deprivation therapy (ADT)
Study: 26526623
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg plus ADT (RAPADT)
Study: 21399536
Drug: AAKG supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAKG supplementation (3,700 mg arginine alpha-ketoglutarate per serving)